Pathogenic antibody response to glucose-6-phosphate isomerase targets a modified epitope uniquely exposed on joint cartilageDepartment of Rheumatology and Inflammation Research, University of Gothenburg, Sahlgrenska Academy, Göteborg, Sweden.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Reumatologi.
Department of Clinical Sciences, Section of Rheumatology, Faculty of Medicine, Lund University, Lund, Sweden; Spenshult Research and Development Center, Halmstad, Sweden.
Section of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Section of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Section of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Center for Medical Immunopharmacology Research, Southern Medical University, Guangzhou, China.
Section of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Department of Clinical Physiology, Sahlgrenska University Hospital, Göteborg, Sweden.
Section of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Department of Rheumatology, Linköping University, Linköping, Sweden.
Department of Rheumatology and Inflammation Research, University of Gothenburg, Sahlgrenska Academy, Göteborg, Sweden; Rheumatology, Sahlgrenska University Hospital, Göteborg, Sweden.
Section of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Visa övriga samt affilieringar
2023 (Engelska)Ingår i: Annals of the Rheumatic Diseases, ISSN 0003-4967, E-ISSN 1468-2060, Vol. 82, nr 6, s. 799-808Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Objectives: To identify the arthritogenic B cell epitopes of glucose-6-phosphate isomerase (GPI) and their association with rheumatoid arthritis (RA).
Methods: IgG response towards a library of GPI peptides in patients with early RA, pre-symptomatic individuals and population controls, as well as in mice, were tested by bead-based multiplex immunoassays and ELISA. Monoclonal IgG were generated, and the binding specificity and affinity were determined by ELISA, gel size exclusion chromatography, surface plasma resonance and X-ray crystallography. Arthritogenicity was investigated by passive transfer experiments. Antigen-specific B cells were identified by peptide tetramer staining.
Results: Peptide GPI293-307 was the dominant B cell epitope in K/BxN and GPI-immunised mice. We could detect B cells and low levels of IgM antibodies binding the GPI293-307 epitopes, and high affinity anti-GPI293-307 IgG antibodies already 7 days after GPI immunisation, immediately before arthritis onset. Transfer of anti-GPI293-307 IgG antibodies induced arthritis in mice. Moreover, anti-GPI293-307 IgG antibodies were more frequent in individuals prior to RA onset (19%) than in controls (7.5%). GPI293-307-specific antibodies were associated with radiographic joint damage. Crystal structures of the Fab-peptide complex revealed that this epitope is not exposed in native GPI but requires conformational change of the protein in inflamed joint for effective recognition by anti-GPI293-307 antibodies.
Conclusions: We have identified the major pathogenic B cell epitope of the RA-associated autoantigen GPI, at position 293-307, exposed only on structurally modified GPI on the cartilage surface. B cells to this neo-epitope escape tolerance and could potentially play a role in the pathogenesis of RA.
Ort, förlag, år, upplaga, sidor
BMJ Publishing Group Ltd, 2023. Vol. 82, nr 6, s. 799-808
Nyckelord [en]
arthritis, experimental, arthritis, rheumatoid, autoantibodies, autoimmunity, inflammation
Nationell ämneskategori
Immunologi inom det medicinska området Klinisk medicin
Identifikatorer
URN: urn:nbn:se:umu:diva-206885DOI: 10.1136/ard-2022-223633ISI: 000951597300001PubMedID: 36858822Scopus ID: 2-s2.0-85152199960OAI: oai:DiVA.org:umu-206885DiVA, id: diva2:1752001
Forskningsfinansiär
Knut och Alice Wallenbergs Stiftelse, 2019.0059Vetenskapsrådet, 2019-01209Vetenskapsrådet, 2019- 01140Reumatikerförbundet, 931878Reumatikerförbundet, 7573312023-04-202023-04-202025-02-18Bibliografiskt granskad